×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
TAK – takeda pharmaceutical company limited american depositary shares (each representing 1/2 of a share of) (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
TAK
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/20
11:41 am
tak
Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform [Yahoo! Finance]
Low
Report
Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform [Yahoo! Finance]
11/20
11:30 am
tak
Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform
Low
Report
Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform
11/19
07:49 am
tak
Latigo Biotherapeutics Appoints Industry Veteran Timothy P. Walbert as Board Chair [Yahoo! Finance]
Neutral
Report
Latigo Biotherapeutics Appoints Industry Veteran Timothy P. Walbert as Board Chair [Yahoo! Finance]
11/4
08:14 am
tak
New Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD [Yahoo! Finance]
Low
Report
New Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD [Yahoo! Finance]
10/31
02:06 am
tak
Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook [Yahoo! Finance]
Low
Report
Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook [Yahoo! Finance]
10/31
02:05 am
tak
Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook
Low
Report
Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook
10/24
08:00 am
tak
Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem
Low
Report
Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem
10/10
04:17 pm
tak
GZERO Summit Japan convenes top political and business leaders to address current geopolitical challenges and opportunities [Yahoo! Finance]
Low
Report
GZERO Summit Japan convenes top political and business leaders to address current geopolitical challenges and opportunities [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
10/31
06:29 am
tak
Form 6-K TAKEDA PHARMACEUTICAL For: Oct 31
Low
Report
Form 6-K TAKEDA PHARMACEUTICAL For: Oct 31
10/31
06:21 am
tak
Form 6-K TAKEDA PHARMACEUTICAL For: Oct 31
Low
Report
Form 6-K TAKEDA PHARMACEUTICAL For: Oct 31
10/31
06:20 am
tak
Form 6-K TAKEDA PHARMACEUTICAL For: Oct 31
Low
Report
Form 6-K TAKEDA PHARMACEUTICAL For: Oct 31
9/26
06:07 am
tak
Form 6-K TAKEDA PHARMACEUTICAL For: Sep 26
Low
Report
Form 6-K TAKEDA PHARMACEUTICAL For: Sep 26
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/2
Takeda Receives Positive CHMP Opinion for ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ Non-Small Cell Lung Cancer
5.1%
4/6 European Commission Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ NSCLC 4.9%
7/31 Takeda Announces FY2019 Key Performance Indicators Aligned with Shareholder Value Creation and Focused on Successful Integration 4.9%
3/4 Takeda Completes Sale of Select OTC and Non-Core Assets to STADA 4.8%
5/17 Canadian Blood Services warns of imminent shortage of take-home immune globulin drug [Toronto Globe and Mail (Ontario, Canada)] 3.1%
2/4 Japan's Takeda forecasts surprise full-year operating profit [Yahoo! Finance News] 3.2%
4/27 Takeda ProThera Collaboration, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha] 3.8%
11/1 Takeda Pharmaceutical Co. Ltd (TKPHF) CEO Christophe Weber on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 3.8%
5/9 Asia Markets: Asian markets mostly gain despite looming U.S. tariff hikes targeting Chinese goods [MarketWatch] 4.1%
4/10 Takeda Pharmaceutical Co Ltd (NYSE: TAK) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $18.00 price target on the stock. 4.1%
4/6 European Commission Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ NSCLC 4.9%
7/31 Takeda Announces FY2019 Key Performance Indicators Aligned with Shareholder Value Creation and Focused on Successful Integration 4.9%
3/4 Takeda Completes Sale of Select OTC and Non-Core Assets to STADA 4.8%
5/17 Canadian Blood Services warns of imminent shortage of take-home immune globulin drug [Toronto Globe and Mail (Ontario, Canada)] 3.1%
2/4 Japan's Takeda forecasts surprise full-year operating profit [Yahoo! Finance News] 3.2%
4/27 Takeda ProThera Collaboration, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha] 3.8%
11/1 Takeda Pharmaceutical Co. Ltd (TKPHF) CEO Christophe Weber on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 3.8%
5/9 Asia Markets: Asian markets mostly gain despite looming U.S. tariff hikes targeting Chinese goods [MarketWatch] 4.1%
4/10 Takeda Pharmaceutical Co Ltd (NYSE: TAK) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $18.00 price target on the stock. 4.1%
TOP News Decliners
3/4
Japan stocks track Wall Street higher, but virus worries weigh [Reuters]
-2.7%
3/4 Japan's Takeda Pharma says it is developing coronavirus drug [Reuters (UK)] -2.7%
7/9 Takeda Continues Ongoing Inclusion in the FTSE4Good Developed Index & MSCI ESG Leaders Index -3.0%
11/8 New Analyses from the Phase 3 HELP Study™ Open-Label Extension in Hereditary Angioedema Evaluate Efficacy and Safety of TAKHZYRO® (lanadelumab-flyo) Injection During Extended Study Treatment Period -3.6%
5/16 Takeda Pharmaceutical Co Ltd (NYSE: TAK) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -3.6%
11/9 2 Biotech Stocks Fighting Alzheimer’s Disease to Own Now [The Motley Fool] -4.0%
10/21 Retrospective Real-World Comparative Analysis Highlights Safety of Vedolizumab and Anti-TNFa Therapies in Biologic-Naïve Patients with Ulcerative Colitis or Crohn’s Disease -5.0%
2/26 Form POS AM TAKEDA PHARMACEUTICAL -6.6%
5/14 Takeda forecasts operating loss as Shire integration costs mount [FT.com - Mergermarket] -8.0%
3/17 The Lancet publishes papers from two studies of Takeda’s dengue vaccine candidate -10.1%
3/4 Japan's Takeda Pharma says it is developing coronavirus drug [Reuters (UK)] -2.7%
7/9 Takeda Continues Ongoing Inclusion in the FTSE4Good Developed Index & MSCI ESG Leaders Index -3.0%
11/8 New Analyses from the Phase 3 HELP Study™ Open-Label Extension in Hereditary Angioedema Evaluate Efficacy and Safety of TAKHZYRO® (lanadelumab-flyo) Injection During Extended Study Treatment Period -3.6%
5/16 Takeda Pharmaceutical Co Ltd (NYSE: TAK) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -3.6%
11/9 2 Biotech Stocks Fighting Alzheimer’s Disease to Own Now [The Motley Fool] -4.0%
10/21 Retrospective Real-World Comparative Analysis Highlights Safety of Vedolizumab and Anti-TNFa Therapies in Biologic-Naïve Patients with Ulcerative Colitis or Crohn’s Disease -5.0%
2/26 Form POS AM TAKEDA PHARMACEUTICAL -6.6%
5/14 Takeda forecasts operating loss as Shire integration costs mount [FT.com - Mergermarket] -8.0%
3/17 The Lancet publishes papers from two studies of Takeda’s dengue vaccine candidate -10.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: